Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Kidney International Reports Année : 2021

Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria

Résumé

Introduction: Givosiran is an RNA interference therapeutic designed to block the synthesis of the aminolevulinic acid (ALA) synthase 1 (ALAS1) enzyme in patients with acute intermittent porphyria (AIP). Givosiran may have adverse effects on the kidney. Methods: We performed a descriptive case series of renal function parameters of all the patients who received givosiran in France. Twenty patients receiving givosiran between March 2018 and July 2020 in France were analyzed: 7 patients in the ENVISION trial and 13 patients treated in collaboration with the Centre de Référence Maladies Rares Prophyries. Results: A transient decrease in renal function was observed in all but 2 patients (90%) within the 3 months following givosiran initiation. None of the patients developed acute kidney injury or disease. Patients of the ENVISION cohort were followed for at least 30 months: 2 patients did not experience estimated glomerular filtration rate (eGFR) loss, 3 patients experienced a modest decline in renal function (–3.4 ml/min per 1.73 m2 per year in average), and 2 patients had a clearly abnormal eGFR loss (–5.8 ml/min per 1.73 m2 per year in average). None of the patients had biochemical signs of active tubular or glomerular injury. One patient’s kidney was biopsied without finding any signs of an active kidney disease and with normal ALAS1 tubular expression. Conclusions: Givosiran is associated with a transient moderate increase in serum creatinine (sCr) without sign of kidney injury. A long-term deleterious impact of ALAS1 inhibition on renal function is not excluded. Because AIP promotes chronic kidney disease, it is difficult to separate the long-term effects of givosiran from the natural progression of the renal disease.
Fichier principal
Vignette du fichier
PIIS246802492101086X.pdf (1.73 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03335343 , version 1 (06-09-2021)

Identifiants

Citer

Hélène Lazareth, Antoine Poli, Yohan Bignon, Arienne Mirmiran, Marion Rabant, et al.. Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria. Kidney International Reports, 2021, 6 (7), pp.1904-1911. ⟨10.1016/j.ekir.2021.04.004⟩. ⟨hal-03335343⟩
59 Consultations
43 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More